Tyra Biosciences, Inc. Stock-Based Compensation
Tyra Biosciences, Inc. (TYRA) reported Stock-Based Compensation of $18.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- Tyra Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $10.23M, a 60.38% increase year-over-year.
- Tyra Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $7.85M, a 22.19% increase year-over-year.
- Tyra Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.63M, a 13.80% increase year-over-year.
- Tyra Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.58M, a 0.05% increase year-over-year.
- Tyra Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $28.01M, a 22.83% increase from fiscal 2024.
- Tyra Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $22.80M, a 68.58% increase from fiscal 2023.
- Tyra Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $13.53M, a 27.74% increase from fiscal 2022.
- Tyra Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $10.59M, a 266.75% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $18.08M 10-Q · filed 2026-08-04 | $25.71M derived: sum of 3 quarters · filed 2026-08-04 | $33.28M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $7.85M 10-Q · filed 2026-05-13 | $15.47M derived: sum of 2 quarters · filed 2026-05-13 | $23.05M derived: sum of 3 quarters · filed 2026-05-13 | $29.43M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $15.20M derived: sum of 2 quarters · filed 2026-03-02 | $21.58M derived: sum of 3 quarters · filed 2026-08-04 | $28.01M 10-K · filed 2026-03-02 |
| 2025-09-30 | $7.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.96M derived: sum of 2 quarters · filed 2026-08-04 | $20.38M 10-Q · filed 2025-11-05 | $27.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $6.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $12.80M 10-Q · filed 2026-08-04 | $19.50M derived: sum of 3 quarters · filed 2026-08-04 | $27.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $6.42M 10-Q · filed 2026-05-13 | $13.12M derived: sum of 2 quarters · filed 2026-05-13 | $20.70M derived: sum of 3 quarters · filed 2026-05-13 | $25.11M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $14.28M derived: sum of 2 quarters · filed 2026-03-02 | $18.69M derived: sum of 3 quarters · filed 2026-03-02 | $22.80M 10-K · filed 2026-03-02 |
| 2024-09-30 | $7.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $11.98M derived: sum of 2 quarters · filed 2025-11-05 | $16.10M 10-Q · filed 2025-11-05 | $20.29M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $8.53M 10-Q · filed 2025-08-14 | $12.71M derived: sum of 3 quarters · filed 2025-08-14 | $17.09M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $4.12M 10-Q · filed 2025-05-08 | $8.30M derived: sum of 2 quarters · filed 2025-05-08 | $12.68M derived: sum of 3 quarters · filed 2025-05-08 | $15.21M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $8.56M derived: sum of 2 quarters · filed 2025-03-27 | $11.09M derived: sum of 3 quarters · filed 2025-03-27 | $13.53M 10-K · filed 2025-03-27 |
| 2023-09-30 | $4.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.91M derived: sum of 2 quarters · filed 2024-11-07 | $9.34M 10-Q · filed 2024-11-07 | $12.25M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $4.96M 10-Q · filed 2024-08-07 | $7.87M derived: sum of 3 quarters · filed 2024-08-07 | $8.89M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $2.43M 10-Q · filed 2024-05-09 | $5.34M derived: sum of 2 quarters · filed 2024-05-09 | $6.36M derived: sum of 3 quarters · filed 2024-05-09 | $9.05M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.93M derived: sum of 2 quarters · filed 2024-03-19 | $6.62M derived: sum of 3 quarters · filed 2024-03-19 | $10.59M 10-K · filed 2024-03-19 |
| 2022-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.71M derived: sum of 2 quarters · filed 2023-11-07 | $7.68M 10-Q · filed 2023-11-07 | $9.55M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $6.66M 10-Q · filed 2023-08-10 | $8.53M derived: sum of 3 quarters · filed 2023-08-10 | $9.04M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.97M 10-Q · filed 2023-05-04 | $5.84M derived: sum of 2 quarters · filed 2023-05-04 | $6.35M derived: sum of 3 quarters · filed 2023-05-04 | $6.68M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $2.38M derived: sum of 2 quarters · filed 2023-03-22 | $2.71M derived: sum of 3 quarters · filed 2023-03-22 | $2.89M 10-K · filed 2023-03-22 |
| 2021-09-30 | $507.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $845.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.02M 10-Q · filed 2022-11-03 | $1.15M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $338.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $512.00K 10-Q · filed 2022-08-04 | $639.00K derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | $174.00K 10-Q · filed 2022-05-05 | $301.00K derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $439.00K 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $312.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |